NEO2734, A NOVEL HIGHLY POTENT ORAL DUAL BET AND P300/CBP BROMODOMAIN INHIBITOR FOR TREATMENT OF HEMATOLGICAL MALIGNANCIES
EHA Learning Center, Bill Brown, 215291
ACUTE MYELOID LEUKEMIA INDUCED TRANSFORMATION OF THE HUMAN BONE MARROW MICROENVIRONMENT PREDICTS CLINICAL OUTCOME
EHA Learning Center, Yiyang Chen, 215292
IMMUNOPHENOTYPIC PROFILING OF LEUKEMIC STEM CELLS TO TRACK FLT3-ITD POSITIVE, CHEMO-RESISTANT CLONES IN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Tiziana Ottone, 215293
ASSESSMENT OF HIGH-RISK MOLECULAR MARKERS IN INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA AS DEFINED BY 2010 ELN RISK CLASSIFICATION
EHA Learning Center, Ekaterina Panina, 215294
MOLECULAR PROLIFE BY NEXT GENERATION SEQUENCING OF ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE: CLINICAL RESULTS FROM THE PROSPECTIVE TRIAL 02/06 OF THE NORTHERN ITALY LEUKEMIA GROUP (NILG)
EHA Learning Center, Orietta Spinelli, 215295
SINGLE CELL SIGNALING PHARMACODYNAMICS AND CLONAL EVOLUTION IN A PHASE 1/2 CLINICAL TRIAL OF SELECTIVE AXL INHIBITOR BEMCENTINIB (BGB324) IN R/R ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME
EHA Learning Center, Monica Hellesøy, 215296
FURTHER EVIDENCE FOR GPR56, BUT NOT CLL-1 (CLEC12A) AS A MARKER FOR LEUKEMIC STEM CELLS IN CD34-POSITIVE ACUTE MYELOID LEUKEMIA
EHA Learning Center, Albert Wölfler, 215297
MOLECULAR ABNORMALITIES IN THERAPY-RELATED ACUTE MYELOID LEUKEMIAS
EHA Learning Center, Gueorgui Balatzenko, 215298
CD123 REDIRECTED NK92 CELLS FOR ACUTE MYELOID LEUKEMIA
EHA Learning Center, Li Zhou, 215299
THE DIFFERENTIAL EXPRESSION OF DNMT3A SPLICE VARIANTS AND THEIR PROGNOSTIC RELEVANCE IN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Stefanie Beinicke, 215300
P53(D281G) MUTATION CAUSES CYTARABINE RESISTANCE VIA PROMOTING WARBURG EFFECT IN ACUTE MYELOID LEUKEMIA CELLS
EHA Learning Center, Kit Man Ng, 215301
EVALUATION OF THE DRUG INTERACTION POTENTIAL OF PRACINOSTAT, A NOVEL HISTONE DEACETYLASE (HDAC) INHIBITOR, WITH CYP1A2 INDUCER CIGARETTE SMOKING AND CIPROFLOXACIN, A CYP1A2 INHIBITOR
EHA Learning Center, Alberto Bernareggi, 215302
SINGLE CENTRE REAL-LIFE EXPERIENCE OF HYPOMETHYLATING AGENTS WITH OR WITHOUT DLI AS SALVAGE THERAPY FOR ACUTE MYELOID LEUKEMIA RELAPSING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION.
EHA Learning Center, Davide Lazzarotto, 215303
CONSOLIDATION CHEMOTHERAPY PREVENTS RELAPSE BY INDIRECTLY REGULATING BONE MARROW ADIPOGENESIS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
EHA Learning Center, Hanyan Liu, 215304
CONTINUING ENASIDENIB TREATMENT FOR PATIENTS WITH MUTANT-IDH2 RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML) WITH STABLE DISEASE MAY RESULT IN IMPROVED RESPONSES AND SURVIVAL OVER TIME
EHA Learning Center, Eytan M. Stein, 215305
PH II TRIAL WITH SELECTIVE ORAL AXL INHIBITOR BEMCENTINIB (BGB324) IN RELAPSED/REFRACTORY AML AND MDS: IDENTIFICATION OF PREDICTIVE AND PHARMACODYNAMIC BIOMARKER CANDIDATES ASSOCIATED WITH PT BENEFIT
EHA Learning Center, Julia Schoelermann, 215306
CYTOGENETIC AND MOLECULAR DRIVERS OF OUTCOME WITH VENETOCLAX-BASED COMBINATION THERAPIES IN TREATMENT-NAÏVE ELDERLY PATIENTS WITH AML
EHA Learning Center, Stephen Strickland, 215307
RANDOMIZED OPEN-LABEL, PHASE III MULTICENTER TRIAL TO EVALUATE AZACITIDINE POST-REMISSION THERAPY IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA
EHA Learning Center, Esther OLIVA, 215308
A PHASE 2B OF ERYASPASE IN COMBINATION WITH LOW-DOSE CYTARABINE AS FIRST-LINE THERAPY IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (ENFORCE - NCT01810705)
EHA Learning Center, X. Thomas, 215309
AN EVALUATION OF CONTROL REGIMENS IN A GROUP OF HIGH RISK OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA FROM TWO COOPERATIVE GROUPS: DATA FROM THE UK NCRI AND DUTCH HOVON STUDIES
EHA Learning Center, Robert Hills, 215310
TP53 ALTERATIONS AND MONOSOMAL KARYOTYPE IN OLDER UNFIT PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH DECITABINE
EHA Learning Center, Heiko Becker, 215311
IDENTIFYING A GENETICALLY DEFINED RISK GROUP OF PEDIATRIC AML PATIENTS THAT CANNOT BE RESCUED AT ALL AFTER THE FAILURE OF THE FIRST LINE TREATMENT
EHA Learning Center, Naghmeh Niktoreh Mofrad, 215312
A PHASE II STUDY OF THE AURORA A KINASE INHIBITOR ALISERTIB COMBINED WITH 7+3 INDUCTION CHEMOTHERAPY IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA
EHA Learning Center, Amir Fathi, 215313
ADMINISTRATION OF BPX-501 CELLS FOLLOWING ALPHA/BETA T-CELL AND B-CELL-DEPLETED HLA HAPLOIDENTICAL HSCT (HAPLO-HSCT) IN CHILDREN WITH ACUTE MYELOGENOUS LEUKEMIA
EHA Learning Center, Neena Kapoor, 215314
COMPARISON BETWEEN MULTIPARAMETRIC FLOW CYTOMETRY AND RT-QPCR ASSAY IN EVALUATING MINIMAL RESIDUAL DISEASE BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION IN NPM1 ACUTE MYELOID LEUKEMIA
EHA Learning Center, Chiara Caprioli, 215315
MRD STATUS AT TRANSPLANTATION IN SECOND OR THIRD CR IS THE STRONGEST FACTOR AFFECTING THE PROBABILITY OF RELAPSE IN AML PATIENTS
EHA Learning Center, Fabio Guolo, 215316
THE CXCR4 INHIBITOR BL-8040 IN COMBINATION WITH CYTARABINE RESULTS IN A SIGNIFICANTLY EXTENDED OVERALL SURVIVAL OF RELAPSED/REFRACTORY AML PATIENTS
EHA Learning Center, Gautam Borthakur, 215317
CELL-FREE DNA MONITORING OF MINIMAL RESIDUAL DISEASE IN AML USING A TARGETED NGS GENE PANEL
EHA Learning Center, Zhiyi Xie, 215318
INTRA-PATIENT DOSE-ESCALATION STUDY OF CRENOLANIB MAINTENANCE THERAPY IN PATIENTS WITH FLT3 MUTANT AML WHO HAD UNDERGONE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLO-HSCT)
EHA Learning Center, Betul Oran, 215319
CONSOLIDATION THERAPY WITH PONATINIB IN COMBINATION WITH CYTARABINE IN PATIENTS FOR FLT3-ITD ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION.
EHA Learning Center, Philippe Rousselot, 215320
PHASE 1/1B STUDY OF PEVONEDISTAT (PEV) AS A SINGLE AGENT OR COMBINED WITH AZACITIDINE (AZA) IN EAST ASIAN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)
EHA Learning Center, SHANG-JU WU, 215321
ANALYSIS OF PHASE I AND PILOT PHASE II DATA REVEAL 2,000 MG/M2 AS THE OPTIMAL DOSE OF CPI-613 IN COMBINATION WITH CYTARABINE AND MITOXANTRONE FOR ELDERLY PATIENTS WITH RELAPSED OR REFRACTORY AML
EHA Learning Center, Timothy Pardee, 215322
CLADRIBINE ADDED TO STANDARD INDUCTION CHEMOTHERAPY FOR ACUTE MYELOID LEUKAEMIA, 4-YEAR EXPERIENCES FROM SLOVENIA
EHA Learning Center, Saša Anžej Doma, 215323
DECITABINE AS SINGLE AGENT FOR TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ELDERLY PATIENTS: A RETROSPECTIVE, MULTICENTER REAL LIFE STUDY OF THE “RETE EMATOLOGICA PUGLIESE” (REP)
EHA Learning Center, Maria Pia Loglisci, 215324
FLUDARABINE, HIGH DOSE CYTARABINE AND IDARUBICIN-BASED INDUCTION (FLAI) IS HIGHLY EFFECTIVE IN AML WITH MUTATED NPM1 WITH CONCOMITANT FLT3-ITD MUTATION IRRESPECTIVELY OF FLT3-ITD ALLELIC BURDEN
EHA Learning Center, Paola Minetto, 215325
CLINICAL CHARACTERISTICS AND PROGNOSIS OF 34 CASES OF ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION AND MLL GENE REARRANGEMENT
EHA Learning Center, Jian Ouyang, 215326
PROGNOSTIC RELEVANCE OF FLT3, NPM1, DNMT3A, IDH1/2 GENE MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS
EHA Learning Center, Irina Martynkevich, 215327
IMPACT OF BCL2 AND ABCG2 OVEREXPRESSION IN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Mario Tiribelli, 215328
ABSOLUTE LYMPHOCYTE COUNT RECOVERY AFTER INDUCTION REMISSION THERAPY IS A STRONG PREDICTOR OF OVERALL SURVIVAL IN ADULT ACUTE MYELOID LEUKAEMIA
EHA Learning Center, Joana Infante, 215329
TYROSINE KINASE INHIBITORS (TKI) IN RELAPSED/REFRACTORY (RR) PATIENTS WITH FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA (AML) CONFER BETTER SURVIVAL THAN CHEMOTHERAPY, DUE TO A BETTER SAFETY PROFILE.
EHA Learning Center, Giovanni Marconi, 215330
ADDITION OF BORTEZOMIB TO AML-LIKE TREATMENT FOLLOWED BY NMA ALLO-SCT IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM
EHA Learning Center, Elisabeth Tolley, 215331
BLAST TRANSFORMATION IN MYELODYSPLASTIC AND MYELOPROLIFERATIVE NEOPLASMS - SIMILARITIES AND DIFFERENCES - A REVIEW OF 100 CASES
EHA Learning Center, Milan Jagurinoski, 215332
QUALITY OF LIFE IN ACUTE LEUKEMIA PATIENTS WITH COMORBID ISCHEMIC HEART DISEASE
EHA Learning Center, Tetiana Lymanets, 215333
BIOMARKER ANALYSIS OF TISAGENLECLEUCEL PRE-INFUSION BIOPSIES OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
EHA Learning Center, Ulrich Jäger, 215334
ACALABRUTINIB IN COMBINATION WITH THE PI3Kδ INHIBITOR ACP-319 IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES.
EHA Learning Center, Paul M. Barr, 215335
TIME TO RELAPSE OF MANTLE CELL LYMPHOMA AFTER INTENSIVE HIGH DOSE CYTARABINE CONTAINING REGIMENS DEFINES PATIENTS RISK FOR DEATH: AN ANALYSIS FROM CENTERS OF THE FONDAZIONE ITALIANA LINFOMI
EHA Learning Center, Carlo Visco, 215336
CC-122-DLBCL-001: PHASE IB STUDY OF CC-122 PLUS RITUXIMAB IN PATIENTS WITH CHEMO-REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
EHA Learning Center, Vincent Ribrag, 215337
EXTRACELLULAR CIRCULATING DNA IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: BIOLOGICAL CORRELATES AND PROGNOSTIC IMPACT
EHA Learning Center, Dino Dujmovic, 215338
ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN THE PHASE 1B ACE-LY-002 STUDY
EHA Learning Center, Martin J. S. Dyer, 215339
OUTCOME OF PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)
EHA Learning Center, Robert Pytlik, 215340
WOMEN WITH DIFFUSE LARGE B CELL LYMPHOMA BENEFIT MORE FROM RITUXIMAB-CONTAINING CHEMOTHERAPY
EHA Learning Center, Huai-Hsuan Huang, 215341
RITUXIMAB, BENDAMUSTINE AND CYTARABINE (R-BAC) IN PATIENTS WITH RELAPSED-REFRACTORY AGGRESSIVE B- CELL LYMPHOMA
EHA Learning Center, Maria Chiara Tisi, 215342
A PROPENSITY SCORE ANALYSIS SHOWS THAT RITUXIMAB DOSE-ADJUSTED EPOCH IMPROVES PROGRESSION-FREE SURVIVAL OF YOUNG PATIENTS AFFECTED BY DOUBLE EXPRESSOR DIFFUSE LARGE B -CELL LYMPHOMAS
EHA Learning Center, Anna Guidetti, 215343
GENETIC EVIDENCE IMPLYING THE COMMON PRECURSOR CELLS FOR PRIMARY AND EXTRA-CENTRAL NERVOUS SYSTEM RELAPSED TUMORS IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
EHA Learning Center, Keiichiro Hattori, 215344
REAL-TIME CELL-OF-ORIGIN SUBTYPE IDENTIFICATION BY GENE EXPRESSION PROFILING IN PATIENTS WITH ABC-TYPE DLBCL IN THE PHASE III TRIAL OF LENALIDOMIDE + R-CHOP (R2-CHOP) VS PLACEBO + R-CHOP (ROBUST)
EHA Learning Center, Annalisa Chiappella, 215345
EXCELLENT OUTCOMES OF OLDER PATIENTS WITH PCNSL USING R-MPV/ARA-C IMMUNOCHEMOTHERAPY WITHOUT WHOLE BRAIN RADIOTHERAPY (WBRT)
EHA Learning Center, Gareth Gregory, 215346
FIRST REPORT ON A SUCCESSFUL SCREENING PROGRAM FOR MYC REARRANGEMENTS AND A PROSPECTIVE CLINICAL TRIAL BASED ON MYC REARRANGEMENT IN NEWLY DIAGNOSED DLBCL PATIENTS IN THE NETHERLANDS
EHA Learning Center, Martine Chamuleau, 215347
A NOVEL IMMUNOHISTOCHEMICAL PROGNOSTIC SCORE BASED ON MYC, BCL2 AND BCL6 EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RETROSPECTIVE ANALYSIS OF DE NOVO DLBCL TREATED WITH RITUXIMAB-CHOP
EHA Learning Center, Mattia Novo, 215348
ASSESSMENT OF BONE MARROW INFILTRATION AND MINIMAL RESIDUAL DISEASE BY MULTIDIMENSIONAL FLOW CYTOMETRY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
EHA Learning Center, M Baile, 215349
ON THE APPLICABILITY OF RHOA GLY17VAL POINT MUTATION TESTING FOR A DIFFERENTIAL DIAGNOSIS OF ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
EHA Learning Center, Yulia Sidorova, 215350
THE ADDITION OF ROMIDEPSIN TO CHOEP FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND TRANSPLANTATION IS FEASIBLE IN UNTREATED PERIPHERAL T-CELL LYMPHOMAS: RESULTS OF PHASE IB FIL-PTCL13
EHA Learning Center, Annalisa Chiappella, 215351
A PHASE I, MULTICENTER, OPEN-LABEL DOSE-ESCALATION STUDY OF CC-122, A NOVEL CEREBLON-MODULATING AGENT, IN ADULT JAPANESE PATIENTS WITH ADVANCED NON-HODGKIN LYMPHOMA OR SOLID TUMOR
EHA Learning Center, Kazuhito Yamamoto, 215352
GLOBAL LONGITUDINAL STRAIN (2D-GLS) IN LYMPHOMA PATIENTS TREATED WITH CHEMOTHERAPY +/- MEDIASTINAL RADIOTHERAPY: EARLY SUBCLINICAL CARDIOTOXICITY IN THE CARDIOCARE PROSPECTIVE OBSERVATIONAL STUDY.
EHA Learning Center, Barbara Botto, 215353
CLINICAL FEATURES, TREATMENT AND PROGNOSTIC FACTORS FOR EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA, NASAL TYPE, IN THE SPANISH POPULATION. A STUDY FROM THE SPANISH GROUP GELTAMO.
EHA Learning Center, EVA GONZALEZ BARCA, 215354
ARE OUTCOMES IMPROVING IN POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER? A RETROSPECTIVE ANALYSIS OF THE LAST 10 YEARS
EHA Learning Center, Nicholas Denny, 215355
PHASE II STUDY WITH OBINUTUZUMAB-DHAP IN RELAPSED/REFRACTORY DLBCL PATIENTS BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION: A STUDY FROM THE FONDAZIONE ITALIANA LINFOMI (GIOTTO STUDY)
EHA Learning Center, Luigi Rigacci, 215356
COMPARISON OF R-CHOP, R-CVP, CHOP, AND CVP FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN TAIWAN: A POPULATION-BASED STUDY, 2009-2013
EHA Learning Center, Huai-Hsuan Huang, 215357
HIGH INCIDENCE OF CARDIOMYOPATHY IN PATIENTS RECEIVING CHOEP14 - POSSIBLE SYNERGISTIC CARDIOTOXICITY OF DOSE-DENSE DOXORUBICIN AND ETOPOSIDE
EHA Learning Center, Igor Aurer, 215358
PROGNOSTIC IMPACT OF SITES OF EXTRANODAL INVOLVEMENT IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN THE RITUXIMAB ERA
EHA Learning Center, Norihito Inoue, 215359
LIPOSOMAL DOXORUBICIN IN AGGRESSIVE B CELL LYMPHOMA SHOWS SIMILAR EFFICACY TO THE CONVENTIONAL FORMULATION: LONG TERM RESULTS FROM A RETROSPECTIVE COHORT STUDY
EHA Learning Center, Ana García-Noblejas, 215360
CLINICAL CHARACTERISTICS AND PROGNOSTIC FACTORS OF HEMOPHAGOCYTIC SYNDROME IN ADULT PATIENTS: A RETROSPECTIVE SINGLE-CENTER STUDY FROM SINGAPORE
EHA Learning Center, Shin-Yeu ONG, 215361
THE IMPACT OF DIFFERENT IMMUNOCHEMOTHERAPY REGIMENS ON SURVIVAL OUTCOMES IN 131 NEWLY DIAGNOSED PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
EHA Learning Center, Gayane Tumyan, 215362
TREATMENT OF TRAUMATIC BLEEDS WITH RECOMBINANT FACTOR XIII-A2 IN PATIENTS WITH CONGENITAL FXIII-A SUBUNIT DEFICIENCY: RESULTS FROM THE MENTOR™6 STUDY
EHA Learning Center, Jolanta Klovaite, 215363
BEVACIZUMAB SIGNIFICANTLY IMPROVES SEVERE EPISTAXIS IN HEREDITARY HEMORRHAGIC TELANGIECTASIA
EHA Learning Center, Silva ZUPANCIC SALEK, 215364
AN AUDIT OF THE USE OF PROTHROMBIN COMPLEX CONCENTRATION
EHA Learning Center, Samantha Bonney, 215365
HAEMOSTATIC ABNORMALITIES OR DEFECTS IN GREEK PATIENTS WITH GAUCHER DISEASE
EHA Learning Center, Veroniki Komninaka, 215366
THALIDOMIDE USE IN HEREDITARY HEMORRHAGIC TELANGIECTASIA: A RETROSPECTIVE EVALUATION OF THE PATIENTS
EHA Learning Center, Mehmet Baysal, 215367
DIAGNOSIS AND MANAGEMENT OF ACQUIRED VON WILLEBRAND DISEASE. A SINGLE CENTER EXPERIENCE
EHA Learning Center, Cristina Santoro, 215368
CONGENITAL FXIII DEFICIENCY IN PAKISTAN
EHA Learning Center, Munira Borhany, 215369
DISSEMINATED INTRAVASCULAR COAGULATION SCORING IN CHILDREN WITH ACUTE LEUKEMIA: IS THERE A SIMPLER AND ECONOMICAL ALTERNATIVE?
EHA Learning Center, Yasmine El Chazli, 215370
EFFECT OF THROMBOELASTOGRAPHY DEFINED COAGULOPATHY IN TRAUMATIC BRAIN INJURY
EHA Learning Center, DIBYENDU DE, 215371
ASSESSMENT AT DIAGNOSIS OF 200 PATIENTS WITH A PNH CLONE OR GPI-DEFICIENT CELLS ≥0.01% ENROLLED IN A NATION-WIDE MULTICENTRIC PROSPECTIVE OBSERVATIONAL STUDY
EHA Learning Center, Orianne Wagner-Ballon, 215372
ASSOCIATION OF AUTOPHAGY-RELATED GENE 5 VARIANTS WITH ACQUIRED APLASTIC ANEMIA IN HAN-CHINESE POPULATION
EHA Learning Center, Yahong You, 215373
PHASE IB STUDY OF THE CXCR4 ANTAGONIST BL8040 COMBINED WITH IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH APLASTIC ANEMIA
EHA Learning Center, Tapan Kadia, 215374
CLINICAL EFFICACY OF THERAPIES FOR TRANSFUSION-DEPENDENT NON-SEVERE APLASTIC ANEMIA: A RETROSPECTIVE COHORT STUDY IN MULTIPLE HOSPITALS
EHA Learning Center, Guangsheng He, 215375
IDIOPATHIC NEUTROPENIA OF INFANCY: DATA FROM THE ITALIAN NEUTROPENIA REGISTRY
EHA Learning Center, Piero Farruggia, 215376
DYNAMICS OF CMV AND EBV LOADS AFTER IMMUNOSUPPRESSIVE TREATMENT WITH RABBIT ATG AND CYCLOSPORINE IN ADULT APLASTIC ANEMIA: A PROSPECTIVE OBSERVATIONAL STUDY
EHA Learning Center, Jong Wook Lee, 215377
PHASE 2 STUDY OF X4P-001: A TARGETED ORAL THERAPY FOR PATIENTS WITH WHIM SYNDROME
EHA Learning Center, David Dale, 215378
SCREENING FOR TELOMERE DISEASE IS IMPORTANT TO IMPROVE THE OUTCOME OF HSCT IN PEDIATRIC PATIENTS SUFFERING FROM SEVERE APLASTIC ANEMIA.
EHA Learning Center, Iris Nederlof, 215379
RESULTS OF HEMATOPOIETIC STEM CELLS TRANSPLANTATION IN CONGENITAL BONE MARROW FAILURE SYNDROMES: SINGLE CENTER EXPERIENCE WITH FOCUS ON TCR ΑΒ+/CD19+ DEPLETION
EHA Learning Center, Zhanna Shekhovtsova, 215380
REACTIVATION OF HEPATITIS B VIRUS INFECTION IN APLASTIC ANEMIA PATIENTS RECEIVING IMMUNOSUPPRESSIVE THERAPY
EHA Learning Center, Guangsheng He, 215381
ADULT PATIENTS WITH ACQUIRED PURE RED CELL APLASIA: COMBINATION OF CYCLOSPORINE A AND CORTICOSTEROIDS PRODUCE BETTER CR
EHA Learning Center, Guangsheng He, 215382
MANAGEMENT OF PATIENTS WITH SEVERE APLASTIC ANAEMIA WHO ARE REFRACTORY TO PLATELET TRANSFUSIONS USING LEUKOCYTE CONCENTRATES
EHA Learning Center, jiali Huo, 215383
IRON OVERLOAD AND MANAGEMENT IN PATIENTS WITH DIAMOND BLACKFAN ANEMIA
EHA Learning Center, Sule Unal, 215384
HIGHER RATE OF DYSMORPHIC FEATURES IN PATIENTS WITH DIAMOND BLACKFAN ANEMIA
EHA Learning Center, Sule Unal, 215385
OPTIMIZING MRD RESPONSE ASSESSMENT USING HIGH-SENSITIVITY PERIPHERAL BLOOD MONITORING DURING TREATMENT WITH IBRUTINIB COMBINED WITH OBINUTUZUMAB OR VENETOCLAX IN CLL .
EHA Learning Center, Andy C. Rawstron, 215386
DYNAMIC OF TELOMERIC PARAMETERS IN RELAPSING OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AN ANALYSIS OF THE FILO ICLL001 BOMP TRIAL
EHA Learning Center, laura bounaix, 215387
HIGH CD9 EXPRESSION IS ASSOCIATED WITH THE MYD88 L265P MUTATION AND REDUCED FAILURE-FREE SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Jennifer Brown, 215388
CERDULATINIB SYNERGISES WITH BCL-2 AND MCL-1 INHIBITORS TO INDUCE SUPERIOR CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Andrew J. Steele, 215389
SELECTIVE CHK1 INHIBITOR MU380 EXHIBITS SINGLE-AGENT ACTIVITY AGAINST CHRONIC LYMPHOCYTIC LEUKEMIA CELLS WITH TP53 MUTATIONS
EHA Learning Center, Miroslav Boudny, 215390

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings